

## Special Issue

# Neoadjuvant and Adjuvant Therapy for Gynecologic Malignancies

### Message from the Guest Editors

Gynecological cancer accounts for approximately 1.3 million deaths a year worldwide. More than 3 million women are expected to be diagnosed with malignant lesions of the female tract annually. Chemotherapy and radiotherapy have been widely used on neo-adjuvant and adjuvant bases to help increase the survival of patients with advanced-stage disease. Although significant benefits have been observed for their use over the last decade, gynecological cancer is far from being defeated; hence, new strategies are evolving in the field. In the present Special Issue, we would like to welcome contributions that will include original research articles (clinical and preclinical), reviews or shorter perspective articles that emphasize the benefit and pitfalls of adjuvant and neoadjuvant therapies in gynecological cancer patients. Topics such as but not limited to neo-adjuvant and adjuvant chemotherapies for ovarian, endometrial, cervical and vulvar cancers, with an emphasis on their impact on survival outcomes and patient-reported outcomes, including quality of life, are welcome in the present Special Issue.

### Guest Editors

Dr. Dimitrios Haidopoulos

Gynaecologic Oncology Unit, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece

Dr. Vasilios Pergialiotis

Gynaecologic Oncology Unit, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece

### Deadline for manuscript submissions

closed (15 August 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/145145](https://mdpi.com/si/145145)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)